Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505921 · ClinicalTrials.gov registry record · Phase 2
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00505921: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00505921 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00505921, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To evaluate the role of autologous and allogenic stem cell transplantation with Campath-1H for patients with peripheral T-cell lymphoma (PTCL). 2. To examine the impact of in-vivo purging with Campath -1H pre-autologous stem transplantation for patients with PTCL. 3. To evaluate the impact of soluble CD52 upon in-vivo purging with Campath-1H. 4. To evaluate the role of Campath -1H in the treatment minimal residual disease after autologous transplantation for PTCL.
Interventions
- DRUG G-CSF
- DRUG BCNU
- DRUG GM-CSF
- DRUG Campath-1H
- DRUG Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2003-03 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00505921
The ClinicalTrials.gov registry entry for NCT00505921 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which G-CSF is the first listed.
NCT00505921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00505921 about?
NCT00505921 is a clinical study titled "Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma". Primary Objectives: 1. To evaluate the role of autologous and allogenic stem cell transplantation with Campath-1H for patients with peripheral T-cell lymphoma (PTCL). 2. To examine the impact of in-vivo purging with Campath -1H pre-autologous stem transplantation for patients with PTCL. 3. To evalu...
What is the current status of trial NCT00505921?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2003-03. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00505921?
The interventions under investigation include: G-CSF (DRUG), BCNU (DRUG), GM-CSF (DRUG), Campath-1H (DRUG), Stem Cell Transplant (DRUG).
Who is sponsoring clinical trial NCT00505921?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.